Lung Cancer

The Lung Cancer Research Foundation awarded $300,000 worth of research grants to two investigators who will investigate strategies to reduce disparities in lung cancer.

Peter J. Mazzone, MD, MPH, pulmonologist and director of the lung cancer program for the Respiratory Institute at Cleveland Clinic, spoke with Healio about presentations on lung cancer given at the CHEST annual meeting, Oct. 17-20, 2021.

In this video, Peter J. Mazzone, MD, MPH, pulmonologist and director of the lung cancer program in the Respiratory Institute at Cleveland Clinic, discusses his presentation on the role of shared decision-making in early-stage lung cancer.

Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.

Concurrent chemoradiotherapy use among patients with stage III non-small cell lung cancer increased significantly following publication of the PACIFIC trial, according to a Dutch study published in JTO Clinical and Research Reports.

The addition of canakinumab to pembrolizumab and chemotherapy failed to extend PFS or OS among patients with advanced non-small cell lung cancer, according to topline results of a randomized phase 3 trial.

A personalized approach to radiation therapy can maximize therapeutic effect across multiple cancer types, according to findings published in The Lancet Oncology.

In this video, Edward B. Garon, MD, MS, discusses findings from lung cancer studies, including the DESTINY-Lung01 trial, presented at ESMO 2021.

Early results from the PRECIsE multicenter study showed shape-sensing robotic-assisted bronchoscopy yielded high sensitivity for malignancy for pulmonary nodules and had a favorable safety profile.

In this video, Edward B. Garon, MD, MS, discusses findings from the TROPION-PanTumor01 study presented at ESMO 2021.